Universal Health Services, Inc.

DB:UHS Stock Report

Market Cap: €12.6b

Universal Health Services Valuation

Is UHS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UHS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UHS (€191) is trading below our estimate of fair value (€499.99)

Significantly Below Fair Value: UHS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UHS?

Key metric: As UHS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UHS. This is calculated by dividing UHS's market cap by their current earnings.
What is UHS's PE Ratio?
PE Ratio12.7x
EarningsUS$1.03b
Market CapUS$13.30b

Price to Earnings Ratio vs Peers

How does UHS's PE Ratio compare to its peers?

The above table shows the PE ratio for UHS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.8x
RHK RHÖN-KLINIKUM
18.6x7.5%€836.7m
FME Fresenius Medical Care
18.6x19.3%€12.2b
M12 M1 Kliniken
18.6x17.5%€311.7m
LIK LIMES Schlosskliniken
23.5xn/a€100.3m
UHS Universal Health Services
12.7x8.5%€13.3b

Price-To-Earnings vs Peers: UHS is good value based on its Price-To-Earnings Ratio (12.7x) compared to the peer average (19.8x).

Price to Earnings Ratio vs Industry

How does UHS's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
UHS 12.7xIndustry Avg. 18.2xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UHS is good value based on its Price-To-Earnings Ratio (12.7x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is UHS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UHS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.7x
Fair PE Ratio24.8x

Price-To-Earnings vs Fair Ratio: UHS is good value based on its Price-To-Earnings Ratio (12.7x) compared to the estimated Fair Price-To-Earnings Ratio (24.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UHS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€191.00
€230.97
+20.9%
9.7%€267.50€198.04n/a15
Nov ’25€187.00
€228.18
+22.0%
9.0%€253.22€194.29n/a15
Oct ’25€208.00
€217.59
+4.6%
7.1%€248.22€198.39n/a16
Sep ’25€212.00
€212.28
+0.1%
7.9%€240.41€170.18n/a16
Aug ’25€197.00
€213.00
+8.1%
8.7%€236.80€172.05n/a15
Jul ’25€171.00
€185.33
+8.4%
9.2%€220.31€145.63n/a15
Jun ’25€171.00
€179.32
+4.9%
7.6%€208.69€144.05n/a15
May ’25€160.00
€177.01
+10.6%
6.5%€194.00€145.50n/a14
Apr ’25€168.00
€175.03
+4.2%
6.9%€193.65€145.24n/a14
Mar ’25€154.00
€164.47
+6.8%
9.8%€191.94€132.88n/a13
Feb ’25€147.00
€149.59
+1.8%
8.5%€175.03€128.97n/a13
Jan ’25€138.00
€141.83
+2.8%
8.1%€160.53€128.42n/a13
Dec ’24€126.00
€137.66
+9.3%
6.5%€155.86€127.44n/a13
Nov ’24€119.00
€143.63
+20.7%
6.4%€160.89€132.50€187.0013
Oct ’24€119.00
€145.87
+22.6%
6.4%€160.97€132.90€208.0014
Sep ’24€124.00
€144.28
+16.4%
7.1%€166.97€129.56€212.0015
Aug ’24€126.00
€143.08
+13.6%
7.7%€166.42€127.32€197.0015
Jul ’24€144.00
€140.65
-2.3%
7.0%€162.71€127.06€171.0015
Jun ’24€123.00
€142.50
+15.9%
5.9%€158.47€129.58€171.0015
May ’24€132.00
€134.49
+1.9%
7.6%€149.74€112.53€160.0015
Apr ’24€114.34
€131.83
+15.3%
8.3%€155.51€115.47€168.0014
Mar ’24€125.62
€135.66
+8.0%
10.0%€157.57€112.55€154.0014
Feb ’24€135.62
€131.66
-2.9%
13.3%€154.39€104.77€147.0015
Jan ’24€131.42
€119.17
-9.3%
11.7%€148.02€103.71€138.0015
Dec ’23€124.80
€118.71
-4.9%
10.3%€150.78€105.64€126.0015
Nov ’23€116.96
€119.17
+1.9%
7.0%€136.65€106.28€119.0015

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Ship Healthcare Holdings

JP¥196.5b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.40

7D

-3.1%

1Y

-4.6%

Sensus Healthcare

US$125.2m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$7.25

7D

16.0%

1Y

272.6%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$53.25

7D

2.4%

1Y

-14.7%